Thousands of catheters are used every day to deliver medication, fluids and nutrition to patients. Despite their ubiquitous use, there has been little innovation and minimal product differentiation paired with current high rates of complications.
We are developing superior indwelling venous access devices by combining our bulk hydrophilic material with a proprietary polymer processing approach.
How is our bulk hydrophilic material better?
Our biomaterial is the first to achieve a high-strength, bio-inert formula with low protein absorption properties.
These features make it the ideal material from which to craft long-term implantable vascular access devices that markedly reduce thrombosis, and in turn, have the potential to significantly decrease the rate of complications and adverse events seen with current devices. Our proprietary biomaterial is less likely to be recognized by the body as a foreign material and therefore in turn will be less likely to trigger the body’s thrombotic response. Without adherent blood products on the catheter to act as a nidus for infection as well as the inability for microbial biofilm to grow across the hydrophilic surface, the device has the potential to significantly lower infectious complication without relying on antimicrobial coatings or additives.